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a‘‘Coronary  pressure  never  lies.’’1 This  was  what  we  were
told  10  years  ago,  just  a  few  months  before  the  publica-
tion  of  the  seminal  FAME  trial,2 arguably  one  of  the  most
important  physiology  trials  ever  published  and  surely  the  one
that  had  the  biggest  impact  on  daily  practice  and  revascula-
rization  guidelines.  It  clearly  demonstrated  the  superiority
of  fractional  ﬂow  reserve  (FFR)  over  the  common  practice
of  visual  estimation  of  stenosis  severity  by  angiography
to  guide  percutaneous  coronary  intervention  of  coronary
lesions.  Also,  at  some  point  during  the  learning  process
of  FFR  measurement,  the  dogma  was  also  implanted  that
‘‘neither  blood  ﬂow  nor  trans-stenotic  pressure  gradient  at
rest  can  determine  whether  a  stenosis  in  a  coronary  artery
will  limit  myocardial  perfusion  under  conditions  of  increas-
ing  demand.  Only  when  hyperemia  is  induced  and  coronary
ﬂow  reserve  is  measured  can  a  relationship  between  stenosis
severity  and  the  presence  of  ischemia  be  demonstrated.’’3
For  this  reason,  research  examining  other  pressure
indices,  such  as  resting  Pd/Pa4 or  contrast-induced  low-
intensity  hyperemia,5 was  paid  little  attention  for  many
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0870-2551/© 2018 Sociedade Portuguesa de Cardiologia. Published by Elears.  Still,  it  must  be  admitted  that  the  idea  was  attrac-
ive  from  a  practical  standpoint:  all  one  needed  to  do  was
o  push  a pressure  wire  through  the  lesion,  induce  hyper-
mia  with  adenosine  and  calculate  FFR.  If  it  was  over  0.80,
perators  could  be  conﬁdent  that  coronary  revascularization
ould  be  safely  postponed  every  time;  on  the  other  hand,
hey  could  be  sure  that  ischemia  was  present  in  all  cases
hen  it  was  0.80  or  less,  and  proceed  with  treatment.  Even
f  Pd/Pa  was  completely  normal  or  a  very  high  contrast  FFR
eading  was  obtained,  we  were  told  that  there  should  be
o  doubt  concerning  the  indication  for  revascularization  as
ong  as  adenosine  FFR  was  below  0.80.  FFR  thrived  for  years
even  if  possibly  not  as  much  as  it  should  have)  in  this  black
s.  white  scenario,  one  that  we,  as  physicians,  would  love
o  have  for  all  medical  conditions:  being  able  to  make  the
ight  decision  for  each  and  every  patient  based  on  a  simple
es-or-no  measurement.
End  of  story?  No:  iFR  enters  the  picture.  In  their  ﬁrst
ajor  paper,  the  ADVISE  study,  published  in  2012,6 the  group
eaded  by  Justin  Davies  (Imperial  College,  London,  UK)  chal-
enged  the  dogma  of  mandatory  hyperemia  and  proposed  a
ew  index  --  the  instantaneous  wave-free  ratio  (iFR)  --  as
n  alternative  to  hyperemic  adenosine  FFR.  Measurement
f  iFR  is  based  on  the  concept  of  the  diastolic  wave-free
eriod,  during  which  coronary  resistance  remains  low  and
table.  This  enables  the  pressure  gradient  measured  during
his  interval  to  be  used  as  a  surrogate  for  coronary  ﬂow,  in
sevier Espan˜a, S.L.U. All rights reserved.
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xactly  the  same  way  as  FFR,  according  to  its  underlying
heory,  but  without  the  need  to  induce  hyperemia.6 After
he  publication  of  the  ADVISE  study,  a  long  and  interesting
iscussion  ensued  between  classical  FFR  ‘believers’7--9 and
he  newcomer  iFR  investigators.10,11 Several  papers  were
ublished  in  major  cardiology  journals  on  both  sides  argu-
ng  the  relative  merits  of  each  of  the  pressure  indices.
rom  a  clinical  perspective  --  probably  the  most  important
-  this  discussion  was  settled  in  2017  with  the  presenta-
ion  at  the  American  College  of  Cardiology  annual  meeting
and  simultaneous  publication  in  the  New  England  Journal
f  Medicine)  of  two  major  randomized  trials:  DEFINE-FLAIR12
nd  iFR-SWEDEHEART.13 These  two  trials,  which  recruited  a
ombined  total  of  over  4500  patients,  clearly  demonstrated
hat  iFR  (with  a  cut-off  set  at  0.89)  was  as  good  as  FFR  for
uiding  revascularization  decisions.
However,  the  introduction  of  iFR  as  an  invasive  assess-
ent  tool  had  another  important  consequence:  there  were
atients  and  lesions  in  which  the  results  of  iFR  and  FFR  would
ot  be  concordant.  In  some,  iFR  would  be  >0.89  (suggest-
ng  absence  of  inducible  ischemia),  but  FFR  would  be  ≤0.80
suggesting  it  was  present),  and  also,  although  less  often,
he  opposite  (iFR<0.89  and  FFR>0.80).  Why  was  this  impor-
ant?  Because  it  clearly  highlighted  the  obvious  question
ome  of  us  had  had  from  the  beginning:  could  FFR  sometimes
ie?  In  fact,  this  is  exactly  what  has  been  observed  when
sing  resting  full-cycle  Pd/Pa  and  contrast  FFR  together  with
denosine  FFR.14
In  the  current  issue  of  the  Journal,  Menezes  et  al.15
escribe  their  experience  with  more  than  150  patients
ssessed  by  both  FFR  and  iFR.  Not  surprisingly,  they  found  a
imilar  pattern.  In  a  proportion  of  cases  (13%),  iFR  and  FFR
id  not  agree,  even  when  using  different  cut-offs  in  a  hybrid
trategy,  in  which  iFR  is  positive  or  negative  when  below  or
bove  the  gray  area  of  0.86-0.93,  respectively.
The  underlying  mechanisms  and  the  implications  of  this
pparent  disagreement  between  iFR  and  FFR  have  been
he  subject  of  intense  debate.  In  a  recent  analysis  of  the
DEAL  study16 --  the  largest  registry  to  date  in  which  both
ressure  and  ﬂow  velocity  were  measured  at  rest  and  dur-
ng  hyperemia  --  Cook  et  al.  suggested  that  disagreement
ould  be  a  reﬂection  of  baseline  ﬂow  and  microvascular
esistance  and  their  response  to  adenosine.  According  to
he  authors,  iFR  would  be  a  better  indicator  of  coronary
ow  (and  ﬂow  reserve),  and  discordance  with  FFR  would
e  the  consequence  of  both  false  positive  (probably  due  to
xcessive  increase  in  coronary  ﬂow  or  to  excessive  decrease
n  microcirculatory  resistance,  both  induced  by  adenosine)
nd  false  negative  FFR  (for  example,  due  to  inadequate
yperemia).
Notwithstanding  this  interesting  theoretical  discussion,
he  clinical  relevance  of  these  discordant  FFR/iFR  patterns
ppears  to  be  less  than  expected.  As  showed  in  a  recent
orean  study,  deferred  lesions  with  discordant  results  (both
FR+/iFR-  and  FFR-/iFR+)  had  a  similar  prognosis  to  lesions
ith  negative  results  in  both  tests,  and  only  deferring  lesions
ith  concordant  positive  FFR  and  iFR  was  associated  with  a
orse  prognosis.17
Yet,  despite  the  clinical  evidence  from  the  two  above-
entioned  randomized  clinical  trials,  iFR  is  still  not  widely
ccepted  in  the  interventional  cardiology  community.  There
s  skepticism  concerning  the  use  of  a  resting  index,  sinceS.  Bravo  Baptista,  L.  Raposo
t  challenges  the  fundamentals  underlying  both  vasodila-
or  non-invasive  stress  testing  and  FFR.18 Additionally,  the
wo  iFR  trials  have  been  criticized  for  including  less  severe
atients  and  lesions  (the  mean  FFR  was  0.83,  compared  to
.71  in  the  FAME  trial).18 Also,  evidence  for  iFR  is  still  rela-
ively  scarce  in  speciﬁc  settings  such  as  complex  patients
nd  acute  coronary  syndromes.  However,  being  easier  to
easure,  iFR  is  particularly  appealing  in  these  situations,
articularly  in  patients  with  ST-elevation  myocardial  infarc-
ion  and  multivessel  disease.  In  these  patients,  the  use  of  iFR
o  assess  non-culprit  lesions  in  the  acute  phase  has  recently
een  analyzed,19 and  a  major  international  randomized  trial
omparing  acute  iFR-guided  full  functional  revascularization
ith  deferred  stress  cardiac  magnetic  resonance  imaging  --
MODERN  (iFR  Guided  Multi-vessel  Revascularization  During
ercutaneous  Coronary  Intervention  for  Acute  Myocardial
nfarction;  ClinicalTrials.gov  identiﬁer  NCT03298659)  --  is
ngoing  and  has  just  started  enrolling  patients.  Portuguese
nvestigators  contributed  signiﬁcantly  to  the  trial  design  and
everal  Portuguese  centers  will  participate  actively  in  the
tudy.
But  is  iFR  the  last  cookie  in  the  jar?  Likely  no.  Other  res-
ing  indices  are  currently  being  developed.  Most  of  them  rely
n  the  fact  that  it  is  apparently  not  necessary  to  measure
he  pressure  gradient  strictly  within  the  wave-free  period,
s  iFR  does:  measurements  performed  using  several  differ-
nt  time  intervals  in  diastole  showed  similar  results  to  iFR
sing  the  Volcano  system.20 Thus,  it  is  only  to  be  expected
hat  other  companies  may  use  this  concept  to  create  their
wn  ‘diastolic  ﬂow  reserve’  indices.  Determination  of  the
argest  resting  pressure  gradient  across  the  full  cardiac  cycle
regardless  of  its  location)  is  another  approach  currently
eing  evaluated.  Portuguese  investigators  lead  the  ﬁrst-in-
an  international  prospective  study  to  test  this  technology,
REDICT  (Performance  of  a  New  REsting  Pressure  Index  Dur-
ng  Invasive  Angiography  Compared  To  Adenosine  Hyperemic
FR;  ClinicalTrials.gov  identiﬁer  NCT03237169).  Results  will
oon  be  available.
We  have  deﬁnitely  moved  forward  from  the  2008  state-
ent  that  ‘‘Coronary  pressure  never  lies’’.  However,  there  is
ndoubtedly  still  much  more  to  learn  in  coronary  physiology,
specially  about  microvascular  function.  Having  Portuguese
enters  involved  in  this  ﬁeld  of  research  is  very  important
nd  surely  a  goal  that  is  worth  pursuing.
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